Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EBIT (2021 - 2025)

Historic EBIT for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $24.0 million.

  • Kiniksa Pharmaceuticals International's EBIT rose 34871.61% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.2 million, marking a year-over-year increase of 24542.61%. This contributed to the annual value of -$45.6 million for FY2024, which is 8104.46% down from last year.
  • Kiniksa Pharmaceuticals International's EBIT amounted to $24.0 million in Q3 2025, which was up 34871.61% from $20.2 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's EBIT's 5-year high stood at $46.4 million during Q3 2022, with a 5-year trough of -$49.3 million in Q1 2021.
  • Moreover, its 5-year median value for EBIT was -$10.9 million (2023), whereas its average is -$8.4 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's EBIT plummeted by 2392592.59% in 2024 and then surged by 1733076.92% in 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EBIT (Quarter) stood at -$36.1 million in 2021, then skyrocketed by 116.74% to $6.0 million in 2022, then tumbled by 98.66% to $81000.0 in 2023, then crashed by 23925.93% to -$19.3 million in 2024, then skyrocketed by 224.47% to $24.0 million in 2025.
  • Its EBIT stands at $24.0 million for Q3 2025, versus $20.2 million for Q2 2025 and $13.3 million for Q1 2025.